Posaconazole is not superior to itraconazole for fungal prophylaxis in allogeneic blood and marrow transplantation

Bone Marrow Transplantation

Volumn 47, Issue 10, 2012, Pages 1379-

  Mossad, S B ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOMANNAN; ITRACONAZOLE; POSACONAZOLE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; DRUG CHOICE; DRUG SUBSTITUTION; INFECTION PREVENTION; LETTER; MIOSIS; MYCOSIS; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SAMPLE SIZE; SYSTEMIC MYCOSIS;

ANTIFUNGAL AGENTS; BONE MARROW TRANSPLANTATION; FEMALE; HUMANS; ITRACONAZOLE; MALE; MYCOSES; TRIAZOLES;

EID: 84867402860     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.34     Document Type: Letter

References (1)

1. Sánchez-Ortega I, Patiño B, Arnan M, Peralta T, Parody R, Gudiol C et al. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplant 2011; 46: 733-739.